Submit Manuscript  

Article Details


Self-microemulsifying Drug Delivery System for Problematic Molecules: An Update

[ Vol. 13 , Issue. 2 ]

Author(s):

Dilpreet Singh, Ashok K. Tiwary and Neena Bedi*   Pages 92 - 113 ( 22 )

Abstract:


Background: The poor bioavailability of a problematic molecule is predominantly due to its high lipophilicity, low solubility in gastric fluids and/or high fist pass metabolism. Self microemulsifying drug delivery system (SMEDDS), a lipidic type IV nano-formulation has been of interest in the field of pharmaceutical research due to its potential for tailoring the physicochemical properties of pharmaceutical molecules.

Methods: This review provides insights on various recent innovations and reports from the past seven years (2012-2019) of self-emulsifying formulations for the delivery of various types of poorly soluble drugs, phytoconstituents and high molecular peptides and gives exhaustive details of the outcome of the endeavors in this field.

Results: Various types of innovative formulations have been molded from SMEDDS like selfemulsifying powders, granules, tablets, pellets, eutectic and cationic formulations. Till date, many research reports and patents have been filed on self-emulsifying dosage forms and many formulations have gained US-FDA approvals which are summarized in the review article.

Conclusion: This review content highlighted the increasing scope of SMEDDS in augmenting the physiochemical properties of an API, the variegated formulation types and the attributes of API that can be improved by SMEDD based formulations.

Keywords:

Solubility enhancement, bioavailability enhancement, SMEDDS, phytoconstituents, peptides, supersaturation, patents.

Affiliation:

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab 147002, Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005



Read Full-Text article